Anxiety Med Recalled

Mylan Institutional Inc. is recalling three lots of alprazolam tablets, 0.25 mg, 10 x 10 per carton (NDC 51079-788-20), because elevated levels of an impurity were detected. The recall was included in the March 27, 2019, US Food and Drug Administration (FDA) Enforcement Report. 

The recall affects alprazolam tablets from lots 3095198, 3096266, and 3098776 (Exp. 5/19). The tablets were distributed throughout the United States and in Puerto Rico. 

Mylan Institutional voluntarily initiated the recall January 18, 2019. On March 20, 2019, the FDA designated it Class II. The classification suggests use of the affected drug could cause temporary or medically reversible adverse health consequences. Although the likelihood is remote, a possibility of serious harm also exists. 

Alprazolam is a prescription benzodiazepine used to treat patients with anxiety and panic disorders. 

—Jolynn Tumolo